Integra Lifesciences (IART) CLO granted 70,305 restricted stock units

Rhea-AI Filing Summary

Hutchinson Michael Damon reported acquisition or exercise transactions in this Form 4 filing.

INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael Damon Hutchinson, EVP and Chief Legal Officer, received a grant of 70,305 restricted stock units tied to common stock. This award will vest 33% on the first and second anniversaries and 34% on the third anniversary of the March 11, 2026 grant date, increasing his directly held RSU position to 159,911 units.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hutchinson Michael Damon

Role EVP, Chief Legal Officer & Sec

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	70,305	$0.00	--

Holdings After Transaction: Restricted Stock Units — 159,911 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hutchinson Michael Damon

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer & Sec

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		70,305		(1)	(1)	Common Stock	70,305	$0	159,911	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

Remarks:

	/s/ Lesha Shinn; Attorney-in-Fact for Michael D. Hutchinson	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IART report for Michael Damon Hutchinson?

INTEGRA LIFESCIENCES reported that EVP and Chief Legal Officer Michael Damon Hutchinson received 70,305 restricted stock units. These RSUs are tied to common stock and represent equity-based compensation, not an open-market stock purchase or sale by the executive.

How many Integra Lifesciences (IART) RSUs were granted in this Form 4?

The Form 4 shows a grant of 70,305 restricted stock units to executive Michael Damon Hutchinson. Each unit represents the right to receive one share of common stock, subject to vesting conditions over a three-year schedule from the March 11, 2026 grant date.

What is the vesting schedule for the 70,305 IART restricted stock units?

The 70,305 restricted stock units vest over three years. According to the disclosure, 33% vest on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary of the March 11, 2026 grant date, assuming continued service.

What are Michael Damon Hutchinson’s RSU holdings in Integra Lifesciences after this grant?

After this award, Michael Damon Hutchinson holds 159,911 restricted stock units directly. This total includes the newly granted 70,305 units and reflects his derivative equity position in the company, which may convert into common shares as the units vest over time.

Does the IART Form 4 indicate any stock sales or purchases by the executive?

The Form 4 reports only an acquisition of restricted stock units as a grant or award. There are no open-market stock purchases or sales disclosed in this filing, and the transaction code "A" identifies it as a compensatory equity award rather than a trade.